Deciphering the Code of Neurodegeneration: The Science of ALTA Drug Candidates
Harnessing Molecular Precision to Combat Neuronal Damage
TDP-43 could be the root cause of neurodegeneration
Normally, this protein is highly expressed during early development, but should gradually disappear when neurons mature and gain adult functions.
A Swift Strike Against Neurotoxicity
If called up later in life, TDP-43 is extremely toxic and can disable adult neurons within 3 weeks. By blocking its source of toxicity, nucleic acid binding, our drugs have the potential to simultaneously eliminate multiple pathological markers.
Discovering Breakthrough Therapies to Transform Lives
Advancing Science for Better Health Outcomes
At Alteron Therapeutics, we are committed to developing first-in-class TDP-43 inhibitors to address the unmet needs of patients with neurodegenerative disorders and cystic fibrosis.
Learn MoreInnovative Research for Future Therapies
Our research pipeline focuses on advancing novel TDP-43 inhibitors through rigorous preclinical and clinical trials.
Learn MoreCollaborating for Scientific Excellence
We actively seek collaborations with leading scientists and institutions to accelerate the development of groundbreaking therapies.
Learn MoreUnleashing the Power of Alteron's Medicines
Learn More-
2017-2019
Incubated and graduated from the Innovation Center in Western Michigan University School of Medicine
-
2020
Efficacy study was performed by the Jackson Lab using an ALS mouse model expressing the wildtype human TDP-43 gene
-
2021-2022
Further advance the preclinical studies and file patents in national phases
-
2023 - Future
Launching IND-enabling studies for ALTA-808 and IND filing